NCT07475377 (Meal Time MS) is a NA clinical trial of Time Restricted Eating in Multiple Sclerosis, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT07475377?

NCT07475377 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT07475377?

Interventions in NCT07475377: Time Restricted Eating, Unrestricted eating.

What condition does NCT07475377 study?

NCT07475377 studies Multiple Sclerosis.

Is NCT07475377 still recruiting?

NCT07475377 is currently not yet recruiting. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT07475377: Meal Time MS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis

Not yet recruiting NA Last updated 18 March 2026

What this trial tests

NA trial testing Time Restricted Eating in Multiple Sclerosis in 22 participants. Not yet recruiting.

Timeline

1 May 2026

Primary endpoint
1 August 2027

31 December 2027

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	22
Start date	1 May 2026
Primary completion	1 August 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Time Restricted Eating
Unrestricted eating

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 64, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if the time an individual eats each day impacts neurological health in people with multiple sclerosis. The main questions the investigators are asking are: 1. Does meal timing affect biomarkers of neuronal health (neurofilament light chain \[NfL\] and BDNF) and inflammation (IL-6, IL-17, TNF-ɑ) in adults with MS. 2. Does meal timing affect expression of circadian clock genes and genes associated with autophagy in adults with MS. Participants will be instructed to start and stop eating at specific times each day based on their group assignment and their personal schedule. They will respond to prompts sent to them on their smartphone to record the times they start and stop eating each day. As a secondary goal, the study will also explore the feasibility of including translocator protein (TSPO)-PET imaging of neuroinflammation in future clinical trials of TRE in people with MS. To accomplish this, imaging will be completed in a subset of 8 participants at the beginning and end of the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Time Restricted Eating

Trials testing the same drug.

NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
NCT07211217 — Time Restricted Eating (TRE) in Bipolar Disorder · NA · not yet recruiting
NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
NCT06686667 — The Feasibility of Overnight Time Restricted Eating and Impact on Glucose Levels in Shift Workers · NA · completed
NCT06477120 — Time-restricted Eating Among Pregnant Females With Severe Obesity · NA · recruiting

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07475377 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07475377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing